

Figure S1. Process of Reviewing Patient Records for Study Inclusion



MC, medical cannabis; MS, multiple sclerosis.

Figure S2. Rate of MC Treatment Discontinuation Across the First 4 Follow-up Visits



MC, medical cannabis.

Patients (n = 11) who were in treatment but had not yet completed 4 follow-up visits at the end of data collection (October 31, 2018) were removed from analysis. Dashed lines represent 95% CIs. Before the fourth follow-up visit, 48% of patients (n = 62) discontinued MC treatment.

Table S1. Results of Self-Rating Scales<sup>a</sup>

n (%)
46
38 (83)
8 (17)
0(0)
0(0)
48
21 (44)
9 (19)
8 (17)
6 (13)
1 (2)
3 (6)

<sup>&</sup>lt;sup>a</sup>Proper psychiatric care was offered to all patients who indicated symptoms of anxiety and/or depression.